Isotype
Whole Humanized Antibody
Description
ADCC-enhanced Benralizumab is a non-fucosylated anti-IL-5R therapeutic biobetter antibody. Creative Biolabs' Afuco™ technology platform allows for the control of glycosylation level, thereby achieving ADCC-Enhanced Anti-IL-5R Benralizumab, a biobetter by reducing fucosylation of the Fc region of Benralizumab, leading to an increased binding affinity for the FcyR receptor on immune effector cells.
More specifically, the afucosylated therapeutic biobetter antibody was generated by recombinant DNA technology. It has been produced in CHO cells that are deficient for fucosylation and purified by affinity chromatography with protein G. The absence of the fucose residue from the N-glycans of IgG-Fc results in dramatic enhancement of antibody-dependent cellular cytotoxicity (ADCC).
Indication
Severe Eosinophilic Asthma
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Benralizumab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Full Name
interleukin 5 receptor subunit alpha
Background
The protein encoded by this gene is an interleukin 5 specific subunit of a heterodimeric cytokine receptor. The receptor is comprised of a ligand specific alpha subunit and a signal transducing beta subunit shared by the receptors for interleukin 3 (IL3), colony stimulating factor 2 (CSF2/GM-CSF), and interleukin 5 (IL5). The binding of this protein to IL5 depends on the beta subunit. The beta subunit is activated by the ligand binding, and is required for the biological activities of IL5. This protein has been found to interact with syndecan binding protein (syntenin), which is required for IL5 mediated activation of the transcription factor SOX4. Several alternatively spliced transcript variants encoding four distinct isoforms have been reported.
Alternative Names
IL5RA; IL5R; Interleukin 5 Receptor Type 3; CDw125; CD125 Antigen; HSIL5R3; Interleukin 5 Receptor, Alpha; IL-5R Subunit Alpha; Interleukin-5 Receptor Alpha Chain; Interleukin-5 Receptor Subunit Alpha; IL-5RA; IL-5 Receptor Subunit Alpha
Cellular Localization
Membrane; Single-pass type I membrane protein.
Involvement in Disease
Diseases associated with IL5RA include Disseminated Eosinophilic Collagen Disease and Hypereosinophilic Syndrome.
Related Pathways
Its related pathways are RET signaling and Signaling by GPCR.
Function
This is the receptor for interleukin-5. The chain binds to IL5.
Post-translational modifications
1.Proteolytically processed under normal cellular conditions. 2.Proteolytically cleaved by caspases during neuronal apoptosis. Cleavage at Asp-739 by either caspase-6, -8 or -9 results in the production of the neurotoxic C31 peptide and the increased production of beta-amyloid peptides. 3. N- and O-glycosylated. 4. Neu5AcNeu5Ac is most likely Neu5Ac 2,8Neu5Ac linked. O-glycosylations in the vicinity of the cleavage sites may influence the proteolytic processing. Appicans are L-APP isoforms with O-linked chondroitin sulfate. 5. Phosphorylation in the C-terminal on tyrosine, threonine and serine residues is neuron-specific. 6. Extracellular binding and reduction of copper, results in a corresponding oxidation of Cys-144 and Cys-158, and the formation of a disulfide bond. In vitro, the APP-Cu(+) complex in the presence of hydrogen peroxide results in an increased production of beta-amyloid-containing peptides. 7. Trophic-factor deprivation triggers the cleavage of surface APP by beta-secretase to release sAPP-beta which is further cleaved to release an N-terminal fragment of APP (N-APP). 8.Beta-amyloid peptides are degraded by IDE.
Groups
Approved, Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Accession Number
DB12023 (DB06024)
Antibody Isotype
Whole Humanized Antibody
Antibody Clone
Benralizumab
Description
Benralizumab is a humanized recombinant monoclonal antibody that targets the alpha chain of the interleukin 5 receptor (CD125) and was developed by MedImmune. Benralizumab was approved by the US FDA in November 2017 for the treatment of severe asthma.
Indication
Severe Eosinophilic Asthma
